BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 16166053)

  • 21. Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
    Isnard F; Guiguet M; Laporte JP; Zunic P; Elloumi M; Chéron N; Deloux J; Van Den Akker J; Lesage S; Fouillard L; Aoudjhane M; Lopez M; Douay L; Gorin NC; Najman A
    Bone Marrow Transplant; 2001 May; 27(10):1045-52. PubMed ID: 11438819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
    Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
    Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
    Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
    Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous bone marrow transplantation for children with AML in first remission.
    Neudorf S; Sanders J; Kobrinsky N; Alonzo TA; Buxton A; Buckley JD; Howells W; Gold S; Barnard DR; DeSwarte J; Kalousek D; Lange BJ; Woods WG
    Bone Marrow Transplant; 2007 Aug; 40(4):313-8. PubMed ID: 17563741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
    Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
    Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy of acute myeloid leukemia in children--results of the AML II/87 multicenter study].
    Hermann J; Zintl F; Krause M; Palme H; Fuchs D; Prager J; Dörffel W; Domula M; Eggers G; Exadaktylos P
    Kinderarztl Prax; 1991 Nov; 59(11):321-7. PubMed ID: 1758135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
    Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
    Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.
    Aladjidi N; Auvrignon A; Leblanc T; Perel Y; Bénard A; Bordigoni P; Gandemer V; Thuret I; Dalle JH; Piguet C; Pautard B; Baruchel A; Leverger G;
    J Clin Oncol; 2003 Dec; 21(23):4377-85. PubMed ID: 14645428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
    Ayash LJ; Ratanatharathorn V; Braun T; Silver SM; Reynolds CM; Uberti JP
    Am J Hematol; 2007 Jan; 82(1):6-14. PubMed ID: 16986128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.